StreetInsider.com News Articles

CONMED Corporation to Participate in the Wells Fargo 21st Annual Healthcare Conference

Wed, 26 Aug 2026 16:05:00 -0400

LARGO, Fla.--(BUSINESS WIRE)-- CONMED Corporation (NYSE: CNMD) today announced its participation in the Wells Fargo 21st Annual Healthcare Conference, which is being held September 8-10, 2026 at the Encore Boston Harbor in Everett, MA.

Management will participate in a fireside chat on Wednesday, September 9th at 1:30 p.m. Eastern Time.

A live audio webcast of the fireside chat will be accessible under the “Events” section of the company’s investor relations website: https://www.conmed.com/en/investor-relations. A replay of the fireside chat will be available for approximately 90 days.

About CONMED Corporation

CONMED is a medical technology company that provides devices

CONMED Corporation to Participate in the Wells Fargo 21st Annual Healthcare Conference

Wed, 26 Aug 2026 16:05:00 -0400

Management will participate in a fireside chat on Wednesday, September 9th at 1:30 p.m. Eastern Time.

About CONMED Corporation

CONMED is a medical technology company that provides devices

CONMED Corporation to Participate in the Wells Fargo 21st Annual Healthcare Conference

Wed, 26 Aug 2026 16:05:00 -0400

Management will participate in a fireside chat on Wednesday, September 9th at 1:30 p.m. Eastern Time.

About CONMED Corporation

CONMED is a medical technology company that provides devices

CONMED Corporation to Participate in the Wells Fargo 21st Annual Healthcare Conference

Wed, 26 Aug 2026 16:05:00 -0400

Management will participate in a fireside chat on Wednesday, September 9th at 1:30 p.m. Eastern Time.

About CONMED Corporation

CONMED is a medical technology company that provides devices

CONMED (CNMD) PT Raised to $45 at BMO Capital

Thu, 30 Jul 2026 09:05:09 -0400

BMO Capital analyst Vik Chopra raised the price target on CONMED (NYSE: CNMD) to $45.00 (from $36.00) while maintaining a Market Perform rating.

CONMED (CNMD) PT Raised to $45 at JPMorgan

Thu, 30 Jul 2026 09:02:17 -0400

JPMorgan analyst Robbie Marcus raised the price target on CONMED (NYSE: CNMD) to $45.00 (from $40.00) while maintaining a Neutral rating.

CONMED (CNMD) PT Raised to $46 at Wells Fargo

Thu, 30 Jul 2026 08:35:12 -0400

Wells Fargo analyst Larry Biegelsen raised the price target on CONMED (NYSE: CNMD) to $46.00 (from $39.00) while maintaining a Equal Weight rating.

CONMED (CNMD) PT Raised to $45 at Piper Sandler

Thu, 30 Jul 2026 07:09:16 -0400

Piper Sandler analyst Matt O'Brien raised the price target on CONMED (NYSE: CNMD) to $45.00 (from $39.00) while maintaining a Neutral rating.

Form 10-Q CONMED Corp For: Jun 30

Wed, 29 Jul 2026 16:14:00 -0400

si-local-file:///var/storage/secattach/20260729/26835156.html

Form 10-Q CONMED Corp For: Jun 30

Wed, 29 Jul 2026 16:14:00 -0400

si-local-file:///var/storage/secattach/20260729/26835156.html

Form 8-K CONMED Corp For: Jul 29

Wed, 29 Jul 2026 16:11:00 -0400

si-local-file:///var/storage/secattach/20260729/26835079.html

Form 8-K CONMED Corp For: Jul 29

Wed, 29 Jul 2026 16:11:00 -0400

si-local-file:///var/storage/secattach/20260729/26835079.html

Conmed (CNMD) Tops Q2 EPS by 27c ; Offers Guidance

Wed, 29 Jul 2026 16:06:54 -0400

Conmed (NYSE: CNMD) reported Q2 EPS of $1.38, $0.27 better than the analyst estimate of $1.11. Revenue for the quarter came in at $343.5 million versus the consensus estimate of $337.46 million.

GUIDANCE:

Conmed sees FY2026 EPS of $4.48-$4.60, versus the consensus of $4.34. Conmed sees FY2026 revenue of $1.36-1.37 billion, versus the consensus of $1.36 billion.

For earnings history and earnings-related data on Conmed (CNMD) click here.

Conmed (CNMD) Tops Q2 EPS by 27c ; Offers Guidance

Wed, 29 Jul 2026 16:06:54 -0400

Conmed (NYSE: CNMD) reported Q2 EPS of $1.38, $0.27 better than the analyst estimate of $1.11. Revenue for the quarter came in at $343.5 million versus the consensus estimate of $337.46 million.

GUIDANCE:

Conmed sees FY2026 EPS of $4.48-$4.60, versus the consensus of $4.34. Conmed sees FY2026 revenue of $1.36-1.37 billion, versus the consensus of $1.36 billion.

For earnings history and earnings-related data on Conmed (CNMD) click here.

CONMED Corporation Reports Second Quarter 2026 Financial Results; Updates Full Year 2026 Guidance